Acute lymphoblastic/lymphocytic leukemia is one of the most common type of cancers that mainly affects children. There are two types of acute lymphocytic leukemia; B-cell type and T-cell type, that can be treated by radiation therapy, chemotherapy, targeted therapy, and others. The global acute lymphocytic leukemia market is expected to witness considerable growth during the forecast period. Increasing prevalence of acute lymphoblastic leukemia is encouraging the players in the market to develop innovative treatments to cure such diseases; thereby, contributing to the growth of the market. According to the National Cancer Institute in 2017, the number of new cases of acute lymphoblastic leukemia in the US was around 1.7 per 100,000 population. With the increasing cases of acute lymphoblastic leukemia, the market players are focusing more on clinical trials, which is expected to fuel the market growth in the near future.

Get Free Sample Copy @ https://www.omrglobal.com/request-sample/acute-lymphoblastic-leukemia-market

The acute lymphoblastic leukemia market is segmented on the basis of cell type, treatment, and end-user. The market on the basis of cell type is bifurcated into B-cell type and T-Cell type. B-cell type segment is expected to contribute significantly to the growth of the market as 75% of acute lymphoblastic leukemia cases in adults develop from precursors of the B-cell lineage in the US, according to the National Institute of Health in 2017. As per treatment, the market is segmented into chemotherapy, radiation therapy, targeted therapy, immunotherapy, and stem cell transplantation. Among these, chemotherapy is expected to hold significant share in the global acute lymphoblastic leukemia market.

Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/acute-lymphoblastic-leukemia-market

Geographically, the global acute lymphoblastic leukemia market is segmented into North America, Europe, Asia-Pacific and Rest of the World. North America is expected to lead the market in 2018 owing to increasing cases of acute lymphoblastic leukemia. Moreover, the presence of key players that uses T-cell receptors for the development of new drugs and therapy is further supporting the market growth in the region. Europe is the expected to follow North America in terms of revenue generation due to the technological advancements in the biotechnology domain.

There are various companies involved in the development of treatments and therapies for acute lymphoblastic leukemia market which includes Pfizer, Inc., Spectrum Pharmaceuticals Inc., Novartis AG, Hoffmann La Roche Ltd., Celgene Corp., Thermo Fisher Scientific, Inc., Eli Lilly & Co., Lonza Group Ltd., and many others. Novartis AG is one of the leading players operating in the global acute lymphoblastic leukemia market. The strong foothold of the company is attributed to its strong geographical presence and robust product line. Further, the approval by the government authorities for its products also aids in enhancing its existing product line. For instance, in October 2017, tisagenlecleucel (KYMRIAH) received FDA approval for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia. With this approval, the company has successfully strengthened its existing product portfolio.

Market Segmentation
Global Acute Lymphoblastic Leukemia Market by Cell Type
B-Cell
T-Cell
Global Acute Lymphoblastic Leukemia Market by Treatment
Chemotherapy
Radiation Therapy
Targeted Therapy
Immunotherapy
Stem Cell Transplantation
Global Acute Lymphoblastic Leukemia Market by End-User
Hospitals and Clinics
Research Institutes

Regional Analysis
North America
United States
Canada
Europe
UK
Germany
Italy
Spain
France
Rest of Europe
Asia-Pacific
China
India
Japan
Rest of Asia-Pacific
Rest of the World

Company Profiles
AbbVie, Inc.
Adaptive Biotechnologies Corp.
Amgen, Inc.
AstraZeneca PLC
Atara Biotherapeutics, Inc.
Athenex, Inc.
Baxter International, Inc.
Blubird Bio, Inc.
Bristol-Myers Squibb Co.
Cabaletta Bio, Inc.
CARsgen Therapeutics Co. Ltd.
Celgene Corp.
Daiichi Sankyo Co. Ltd.
Deciphera Pharmaceuticals LLC
Eisai Co Ltd.
Eli Lilly and Co
Erytech Pharma, SA
F. Hoffmann-La Roche Ltd.
Formula Pharmaceuticals, Inc.
Gamida Cell Ltd.

Genmab A/S
ImmunoGen Inc.
Juno Therapeutics, Inc.
Kite Pharma, Inc.
Lonza Group Ltd.
Medigene AG
NexImmune Inc.
Nimbus Therapeutics Inc.
Nohla Therapeutics, Inc.
Protheragen, Inc.
Spectrum Pharmaceuticals, Inc.
Takeda Pharmaceutical Co. Ltd.
Thermo Fisher Scientific, Inc.

For More Customized Data, Request for Report Customization @https://www.omrglobal.com/report-customization/acute-lymphoblastic-leukemia-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari

Email: [email protected]
Contact no: +91 780-304-0404